and/or

54 Trending Topics found

MSK Researchers Study Blood Biomarkers to Help Answer Questions about Why Some Patients Don't Respond to Immunotherapy

Researchers from Memorial Sloan Kettering Cancer Center (MSK) and their colleagues at the University of Pennsylvania (UPenn), in collaboration with the Parker Institute for Cancer Immunotherapy (PICI), studied changes in the blood of patients with stage IV melanoma who were all treated with the PD-1 drug pembrolizumab. Researchers looked at circulating immune cells called T cells that showed signs of being “reinvigorated” by the PD-1 therapy. For more information or to arrange interviews please e-mail Rebecca Williams at williamr@mskcc.org.

  • Monday, April 10, 2017

From Precision Medicine to Immunotherapy: Promising New Research at the 2017 AACR Annual Meeting

Memorial Sloan Kettering experts are available to comment on the promising new research presented at the American Association for Cancer Research (AACR) Annual Meeting, including precision medicine, immunotherapy, screening, prevention, health equity, data sharing, the Cancer Moonshot Initiative, and more. For more information and to set up interviews or access photos and video, email Nicole H. McNamara at mcnamarn@mskcc.org.

  • Friday, March 31, 2017

MSK Researchers Identify First Evidence of Epigenetic Role in Breast Cancer

Researchers at Memorial Sloan Kettering Cancer Center have identified, for the first time, an epigenetic mechanism promoting breast cancer. The team found that inhibition of the PI3K pathway leads to activation of ER-dependent transcription through the epigenetic regulator KMT2D. These findings provide a rationale for epigenetic therapy in patients with PIK3CA-mutant, ER-positive breast cancer. While epigenetic factors have been known to play an important role in various cancers such as leukemia and lymphoma, this is the first evidence found in breast cancer. This research co-led by José Baselga, MD, PhD, Physician-in-Chief and Chief Medical Officer, appears in the March 24, 2017 issue of Science. For more information on this work and to speak with the study authors, contact mcnamarn@mskcc.org.

  • Thursday, March 23, 2017

MSK Researchers Look for Answers That May Lead to Advances in Treating Leptomeningeal Metastasis, a Virtually Untreatable Complication

Leptomeningeal metastasis, cancer that has spread to the areas surrounding the brain and spinal cord, has long been a formidable clinical challenge for oncologists. Researchers at Memorial Sloan Kettering Cancer Center have identified the molecular basis of this increasingly prevalent complication of cancer. With the help of a mouse model, researchers have identified a drug strategy that may combat this virtually untreatable condition. This research by Joan Massagué, PhD, Adrienne Boire, MD, PhD, and colleagues, was published in the March 9, 2017 issue of Cell. For more information on this work and to speak with the study authors, contact mcnamarn@mskcc.org.

  • Thursday, March 9, 2017

Memorial Sloan Kettering Researcher Examines Disparity in Job Retention in Breast Cancer Patients

Breast cancer affects one in eight women in the United States, with approximately 70 to 80 percent of employed breast cancer survivors returning to work three to eighteen months following diagnosis. Job loss can have devastating financial consequences, including increased risk of bankruptcy and debt. Victoria Blinder, MD, medical oncologist at Memorial Sloan Kettering, conducted a longitudinal study of a racially and ethnically diverse sample of employed women undergoing treatment for stage I-III breast cancer in New York City. For more information on this study, published in Health Affairs on February 6, 2017, and to speak with the study author, contact mcnamarn@mskcc.org.

  • Tuesday, February 7, 2017

Major Developments in Radiation Therapy: ASTRO Annual Meeting

The 2016 ASTRO Annual Meeting will take place in Boston from September 25 to 28. Featuring new insights and discoveries from leading institutions around the world, this scientific forum will include presentations and data that could affect the way cancer care is planned and delivered. Memorial Sloan Kettering radiation oncologists are available to comment on meeting news and presentations. Follow the meeting live on Twitter using the hashtag #ASTRO16. For more information or to speak with an expert, contact mediastaff@mskcc.org.

  • Friday, September 23, 2016

Memorial Sloan Kettering Study Shows Targeted Therapy for Advanced Sarcoma Extends Survival by Nearly a Year

A new drug is being shown to extend the lives of patients with advanced soft tissue sarcoma by almost a year. The results of a multicenter phase II trial evaluating the efficacy and safety of olaratumab in combination with doxorubicin chemotherapy was published in The Lancet on June 9. William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), served as corresponding author on this study, which met its primary endpoint of progression-free survival and showed a statistically significant improvement in overall survival. To arrange an interview with Dr. Tap, please email mcnamarn@mskcc.org.

  • Friday, June 10, 2016

MSK Research and Experts at the 2016 ASCO Annual Meeting

MSK researchers are presenting nearly 120 studies at the 2016 Annual Meeting of the American Society of Clinical Oncology.

  • Friday, June 3, 2016

Memorial Sloan Kettering Cancer Center Hosts Roundtable Discussion with Vice President Biden and Leaders of the Cancer Community

Vice President Joseph Biden visited Memorial Sloan Kettering Cancer Center (MSK) for a roundtable discussion with MSK experts and members of the cancer community. The candid conversation, inspired by the “moonshot” initiative announced by President Obama, was led by Craig Thompson, MD, President and CEO of MSK. MSK’s Carol Brown, MD, Ross Levine, MD, and Robert Sidlow, MD, were also active participants in the discussion. For more information about the event or to request an interview with a MSK roundtable participant, please e-mail mediastaff@mskcc.org.

  • Thursday, May 26, 2016

Despite Pressing Need, Memorial Sloan Kettering Survey Finds Most Americans Unlikely to Enroll in Clinical Trials

The lack of participation in clinical research may be the Achilles heel facing today’s cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of MSK, only 35 percent of Americans indicated that they were “likely” to enroll in a clinical trial. For more information or to schedule an interview, please contact mediastaff@mskcc.org.

  • Monday, May 23, 2016